New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Infection in Adults a

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Alios BioPharma, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1. DeVincenzo JP, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 19 November 2015.

2. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415-20.

3. Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): For Healthcare Professionals [Online]. Available at:http://www.cdc.gov/rsv/clinical Last accessed October 2015.

4. World Health Organization. Initiative for Vaccine Research: Acute Respiratory Infections [Online]. Available at: http://apps.who.int/vaccine_research/dis... Last accessed October 2015.

5. Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-55.

Photo:

http://photos.prnewswire.com/prnh/201403...

http://photos.prnewswire.com/prnh/20151118/289008-INFO

CONTACT: Media Contact: Daniel De Schryver (Global)Mobile: +49-173-76-89-149Email: ddschryv@its.jnj.com